MPS II launches in Stockholm with Topcon Sweden and Dr. Scott Mackie

Topcon SwedenLeading optometrist Dr Scott Mackie spoke at the Optikmassen workshops in Stockholm on the 28th and 29th August about measuring macular pigment density when screening for macular degeneration (AMD) risk. This officially launched our MPS II screener in Sweden, with our exclusive distributor Topcon.

The lectures explored how the Macular Pigment Optical Density (MPOD) is measured and how this score indicates the likelihood of developing AMD. The MPS II device gives a fast, simple MPOD reading which is easy to interpret. Generally, if risk factors such as smoking and family history are present alongside a low MPOD score, supplementation and lifestyle changes are suggested to lower the risk of developing AMD.

Prevention of AMD with early screening and supplementation is vital, as there is currently no cure for the condition. I If the condition is undetected and deteriorates to an advanced stage (Wet/Neovascular AMD) many patients have to take medication or endure uncomfortable treatments to slow degeneration and eventual sight loss. The Macular Pigment Screener II (MPS II) can detect those with low MPOD who are at greater risk allowing optometrists to support their patients in the prevention of AMD. Early screening is essential in the prevention of this disease.

“We’re excited to bring this new concept to Sweden, in partnership with Topcon. With MPS II optometrists now have the ability to screen their patients who are at the greatest risk, allowing them to make lifestyle choices and take supplementation to increase their MPOD and lower the risk of developing AMD. ” said Denise Axten, Elektron Technology.

Learn more about  or read Dr Scott Mackie’s MPS II and macular pigment screening whitepaper. If you are an optometrist in Sweden find out more about MPS II and supplementation from Topcon Sweden.

Leave a Reply

Your email address will not be published. Required fields are marked *